AI assistant
INSULET CORP — Director's Dealing 2021
Jul 2, 2021
30258_dirs_2021-07-02_5327e1a7-a845-4645-adfe-292e0ddfbb73.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: INSULET CORP (PODD)
CIK: 0001145197
Period of Report: 2021-05-14
Reporting Person: Petrovic Shacey (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-14 | Common Stock | G | 25905 | — | Disposed | 15684 | Direct |
| 2021-05-14 | Common Stock | G | 25905 | — | Acquired | 25905 | Indirect |
| 2021-07-01 | Common Stock | M | 15000 | $30.58 | Acquired | 30779 | Direct |
| 2021-07-01 | Common Stock | S | 15000 | $278.56 | Disposed | 15779 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-07-01 | Employee Stock Option (Right to Buy) | $30.58 | M | 15000 | Disposed | 2025-02-09 | Common Stock (15000) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 87495 | Indirect |
Footnotes
F1: On May 14, 2021, the reporting person gifted 25,905 shares of Insulet common stock to a family trust of which the reporting person is the settlor and a trustee. The beneficiaries of the trust are members of the reporting person's immediate family.
F2: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan.
F3: Includes 95 shares acquired under the Insulet Corporation Employee Stock Purchase Plan on May 28, 2021.
F4: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $274.695 to $280.55. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price.
F5: This option is subject to a four-year vesting period, with 25% of the total award vesting one year after the grant date and the remainder vesting in equal quarterly installments each quarter thereafter for 12 quarters, subject to continued employment.